Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?

Area of Science:

• Cardiology
• Neurology
• Public Health

Background:

• Hyperlipidemia is a major risk factor for coronary heart disease (CHD).
• The link between low-density lipoprotein cholesterol (LDL-C) and stroke has been debated.
• Recent evidence confirms LDL-C's role in stroke and the effectiveness of lipid-lowering therapies.

Purpose of the Study:

• To review the evidence for lipid-lowering therapy in patients with atherosclerotic cardiovascular disease (ASCVD).
• To highlight the undertreatment of secondary prevention patients, particularly those with concomitant CHD and cerebrovascular disease (CeVD).

Main Methods:

• Literature review of epidemiological data and clinical trial results.
• Analysis of current international lipid guidelines and clinical practice patterns.

Main Results:

• Lipid-lowering drugs are proven to reduce CHD morbidity.
• LDL-C lowering strategies are effective in reducing stroke incidence.
• Despite guidelines recommending aggressive treatment, secondary prevention patients with CHD and CeVD are often undertreated.

Conclusions:

• Lowering LDL-C is crucial for both CHD and stroke prevention.
• There is a significant gap between recommended and actual lipid-lowering therapy in high-risk patients.
• Aggressive lipid management is essential for secondary prevention in patients with ASCVD, including those with CeVD.